Peripheral immune biomarkers of survival in patients with resectable dedifferentiated liposarcomas (DDLPS) and undifferentiated pleomorphic sarcomas (UPS) treated with neoadjuvant nivolumab plus /- ipilimumab (neoICB)-MedSci.cn

Peripheral immune biomarkers of survival in patients with resectable dedifferentiated liposarcomas (DDLPS) and undifferentiated pleomorphic sarcomas (UPS) treated with neoadjuvant nivolumab plus /- ipilimumab (neoICB)

Nassif, EF; Keung, EZ; Jiang, P; Reuben, A; Crosby, S; Mathew, G; Lazar, A; Torres, K; Wang, WL; Guadagnolo, A; Bishop, A; Hunt, KK; Bird, J; Lewis, V; Conley, AP; Wargo, JA; Somaiah, N; Roland, CL

ANNALS OF ONCOLOGY, 2022; 33 (7): S1229

科室
- - 订阅+
  - 更多科室
工具
服务